USE OF INSULIN PUMP IN CYSTIC FIBROSIS

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。近75%的CF患者有糖耐量受损，15%的患者有明显的糖尿病，称为CF相关糖尿病或CFRD。这是由胰岛素抵抗和胰岛素缺乏的组合引起的。1998年CF Foundation Consortium认可CF中的葡萄糖耐量的4个主要类别：1）正常葡萄糖耐量（FBG <126; pp <150）; 2）受损葡萄糖耐量（FBG <126; pp 151-200）; 3）无空腹高血糖症的糖尿病（FBG <126; pp >200），一种类型的受损葡萄糖耐量。4)糖尿病伴空腹高血糖。只有患有FH的CFRD患者常规接受胰岛素治疗。CFRD最有效的胰岛素治疗方案是在进餐时注射多种胰岛素（通常每天3-5次注射）。许多CF患者不愿意接受大量的胰岛素注射。 我们假设使用胰岛素泵将通过改善体重、瘦体重、全身蛋白质周转、肝葡萄糖生成（HGP）和血糖控制，为伴有空腹高血糖（FH）的CF相关糖尿病（CFRD）和不伴FH的CFRD患者提供有效治疗。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Nearly 75% of patients with CF have impaired glucose tolerance and 15% have frank diabetes, called CF related diabetes or CFRD. This is caused by a combination of insulin resistance and insulin deficiency. The 1998 CF Foundation Consortium recognized 4 major categories of glucose tolerance in CF: 1) Normal glucose tolerance (FBG <126; pp <150); 2) Impaired glucose tolerance (FBG <126; pp 151-200); 3) Diabetes w/o fasting hyperglycemia (FBG <126; pp >200), a type of impaired glucose tolerance. 4) Diabetes with fasting hyperglycemia. Only patients who have CFRD with FH routinely receive insulin treatment. The most effective insulin regimen for CFRD is multi-insulin injections around the time of meals (generally 3-5 shots per day). Many CF patients have been reluctant to take this large number of insulin injections. We hypothesize use of the insulin pump will provide effective therapy for patients with CF related diabetes (CFRD) with fasting hypergycemia (FH) and CFRD without FH by improving body weight, lean body mass, whole body protein turnover, hepatic glucose production (HGP), and blood sugar control.